文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

实验性失血性休克中靶向微血管渗漏的治疗:系统评价与Meta分析

Therapeutically Targeting Microvascular Leakage in Experimental Hemorrhagic SHOCK: A Systematic Review and Meta-Analysis.
PubMed 文献 · Shock · 2021-01-01
一句话结论实验性失血性休克液体复苏基础上,靶向氧化应激与凋亡等通路的药物可减少微血管渗漏,血管活性药无效。

该系统评价与Meta分析检索PubMed、EMBASE.com和Cochrane Library(2021年1月),纳入45项1973—2020年发表的失血性休克临床前研究,评估在标准液体复苏基础上加用治疗药物对血管渗漏(水肿、大分子外渗或糖萼降解)的影响。多数研究除失血性休克外还诱导了创伤,主要测试肺与肠道血管床,共54种治疗药物。44种(81%)药物在至少一个器官中有效减少微血管渗漏、水肿形成或糖萼降解;靶向氧化应激与凋亡是最有效的策略(SMD -2.18,CI [-3.21, -1.16],P < 0.0001),血管活性药物无效(SMD -0.86,CI [-3.07, 1.36],P = 0.45)。作者认为未来研究应探讨靶向这些通路能否恢复微循环灌注并减少器官损伤。

要点

  • 实验性失血性休克液体复苏基础上,44种(81%)治疗药物在至少一个器官中有效减少微血管渗漏、水肿形成或糖萼降解。
  • 靶向氧化应激与凋亡是最有效的策略(SMD -2.18,CI [-3.21, -1.16],P < 0.0001)。
  • 血管活性药物在减少微血管渗漏方面无效(SMD -0.86,CI [-3.07, 1.36],P = 0.45)。
  • 纳入研究主要测试肺与肠道血管床,多数研究除失血性休克外还诱导了创伤。
  • 作者认为未来研究应探讨靶向这些通路能否恢复微循环灌注并减少失血性休克后的器官损伤。

适用人群与场景

  • 实验性失血性休克(临床前研究)模型,在标准液体复苏基础上加用治疗药物。

研究设计与关键结果

  • 系统评价与Meta分析,纳入45项1973—2020年发表的临床前研究,共测试54种不同治疗药物,主要针对肺与肠道血管床,多数研究除失血性休克外还诱导了创伤。
  • 44种治疗药物(81%)在至少一个器官中有效减少微血管渗漏、水肿形成或糖萼降解。
  • 靶向氧化应激与凋亡是最有效的策略(SMD -2.18,CI [-3.21, -1.16],P < 0.0001)。
  • 血管活性药物在减少微血管渗漏方面无效(SMD -0.86,CI [-3.07, 1.36],P = 0.45)。
  • 细胞代谢、炎症、内皮屏障调节、性激素相关通路的药物调节在实验性失血性休克液体复苏中有效减少微血管渗漏。

证据类型、等级与局限

  • 证据类型:系统评价与Meta分析(临床前研究)。
  • 注册号:CRD42018095432。
  • 局限:原文未报告局限性

对床旁实践的改变

  • 作者认为,靶向细胞代谢、炎症、内皮屏障调节、性激素尤其是氧化应激与凋亡通路的药物调节,在实验性失血性休克液体复苏中可有效减少微血管渗漏。
  • 作者认为,未来研究应探讨靶向这些通路能否恢复微循环灌注并减少失血性休克后的器官损伤。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Microvascular leakage is proposed as main contributor to disturbed microcirculatory perfusion following hemorrhagic shock and fluid resuscitation, leading to organ dysfunction and unfavorable outcome. Currently, no drugs are available to reduce or prevent microvascular leakage in clinical practice. We therefore aimed to provide an overview of therapeutic agents targeting microvascular leakage following experimental hemorrhagic shock and fluid resuscitation.

METHODS: PubMed, EMBASE.com, and Cochrane Library were searched in January 2021 for preclinical studies of hemorrhagic shock using any therapeutic agent on top of standard fluid resuscitation. Primary outcome was vascular leakage, defined as edema, macromolecule extravasation, or glycocalyx degradation. Drugs were classified by targeting pathways and subgroup analyses were performed per organ.

RESULTS: Forty-five studies, published between 1973 and 2020, fulfilled eligibility criteria. The included studies tested 54 different therapeutics mainly in pulmonary and intestinal vascular beds. Most studies induced trauma besides hemorrhagic shock. Forty-four therapeutics (81%) were found effective to reduce microvascular leakage, edema formation, or glycocalyx degradation in at least one organ. Targeting oxidative stress and apoptosis was the predominantly effective strategy (SMD: -2.18, CI [-3.21, -1.16], P < 0.0001). Vasoactive agents were found noneffective in reducing microvascular leakage (SMD: -0.86, CI [-3.07, 1.36], P = 0.45).

CONCLUSION: Pharmacological modulation of pathways involved in cell metabolism, inflammation, endothelial barrier regulation, sex hormones and especially oxidative stress and apoptosis were effective in reducing microvascular leakage in experimental hemorrhagic shock with fluid resuscitation. Future studies should investigate whether targeting these pathways can restore microcirculatory perfusion and reduce organ injury following hemorrhagic shock.

SYSTEMATIC REVIEW REGISTRATION NUMBER: CRD42018095432.

来源:Shock,查看原文。版权归原作者所有。

参考来源

  1. van Leeuwen ALI, Borgdorff MP, Dekker NAM, et al. Therapeutically Targeting Microvascular Leakage in Experimental Hemorrhagic SHOCK: A Systematic Review and Meta-Analysis. Shock. 2021. PMID: 33927137. doi:10.1097/SHK.0000000000001796

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。